3. Procedure
Participants attended a screening session at the study site (Swinburne University of Technology, Melbourne) to assess study eligibility, followed by a baseline session, a supply of study treatment (240 mg daily tablets of kava or placebo), and a follow-up at eight weeks. Sociodemographic information included age in years, sex (male/female), BMI, medical conditions, alcohol consumption per week, allowable medication use (prophylactics), and eligible vitamins and supplements as determined by the protocol for the KGAD study [